Hofseth Biocare ASA (HOFBF) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hofseth BioCare ASA has announced the transfer of its drug candidate MA-022a, aimed at treating eosinophil-related conditions like asthma and eosinophilic esophagitis, to its subsidiary HBC Immunology Inc. This move, valuing the underlying patent at $4.5 million, will see HBC receiving shares in HBCI and is expected to result in a financial gain for HBC in the second quarter of 2024. The drug candidate demonstrates promise with a different treatment profile that could improve patient outcomes in these conditions.
For further insights into HOFBF stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money